Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this HIV and hepatitis C drugmaker have returned -7.5% over the past month versus the Zacks S&P 500 composite's -0.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has lost 7.5% over this period. Now the key question is: Where could the stock be headed in the ...